Coexisting conditions and medicines that promote weight gain can blunt response, so adjustments may be needed
However, semaglutide has FDA-approved uses under specific brand names and indications, while retatrutide remains investigational
Some signs or dumping can be palpitations or racing heart, a sweaty and clammy feeling, and abdominal pain and or cramping, weakness, fatigue, dizziness and sometimes diarrhea
From randomization to the first event in the presence of competing risks
Future work will likely focus on subgroups: patients with established heart disease versus those at risk, people with heart failure with preserved versus reduced ejection fraction, and populations with chronic kidney disease where cardiovascular and renal outcomes overlap